NCT01996618

Study to Reduce Symptoms of Premature Beats With Ranolazine

Reduction of Symptomatic Ventricular Premature Beats With Ranolazine

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Walter Reed National Military Medical Center · Federal
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Investigate whether ranolazine, a novel anti-anginal agent with antiarrhythmic properties, has a role in the management of symptomatic ventricular premature beats.

Detailed description

The main objective is to compare the effect of ranolazine versus placebo on premature ventricular beats (using 24-hour ambulatory electrocardiographic monitoring) for subjects with symptomatic palpitations. Subject population will consist of seventy-two adult subjects of both sexes who have greater than 1,000 premature ventricular beats during initial monitoring.

Conditions

• Premature Ventricular Beats

Interventions

Type	Name	Description
DRUG	Ranolazine	After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days.

Timeline

• Start date: 2014-01-01
• Primary completion: 2016-06-01
• Completion: 2016-07-01
• First posted: 2013-11-27
• Last updated: 2015-05-01

Locations

1 site across 1 country: United States